GANNON STEVEN

SEC source: 0001193125-26-349351 · ownership.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,870

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $64.0517 to $64.078, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001193125-26-256121 · ownership.xml · derivative · entry 5

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,593

Underlying: Common Shares · 1,593 shares

Expires not disclosed

F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

SEC source: 0001193125-26-256121 · ownership.xml · derivative · entry 4

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,507

Underlying: Common Shares · 10,507 shares

Expires 2036-06-02

F4 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

SEC source: 0001193125-26-256121 · ownership.xml · derivative · entry 3

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,645 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F1 · derivative.exercise_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F1 · derivative.expiration_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

SEC source: 0001193125-26-256121 · ownership.xml · nonDerivative · entry 2

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,870

F2 · shares: Represents the number of Common Shares withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs, and does not represent a sale.

F3 · price: Represents the closing price of Common Shares on June 1, 2026 for purposes of net settlement calculations.

SEC source: 0001193125-26-256121 · ownership.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F1 · price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

SEC source: 0001193125-26-222369 · ownership.xml · derivative · entry 2

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 3,500 shares

Expires 2026-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

SEC source: 0001193125-26-222369 · ownership.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,641

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-083321 · ownership.xml · derivative · entry 3

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,645

Underlying: Common Shares · 2,645 shares

Expires not disclosed

F3 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.

F3 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.

SEC source: 0000950170-25-083321 · ownership.xml · derivative · entry 2

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,012

Underlying: Common Shares · 17,012 shares

Expires 2035-06-04

F2 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.

SEC source: 0000950170-25-083321 · ownership.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,141

F1 · shares: Shares automatically sold in payment of transfer fee for transfer of shares to an alternate brokerage account.

SEC source: 0000950170-25-073746 · ownership.xml · derivative · entry 2

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,144 shares

Expires 2025-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

SEC source: 0000950170-25-073746 · ownership.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,144

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-069464 · ownership.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,542

Underlying: Common Shares · 15,542 shares

Expires 2034-06-04

F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2025 or (ii) the day before the date of the issuer's 2025 annual meeting of shareholders.

SEC source: 0000950170-24-068906 · ownership.xml · derivative · entry 6

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,000 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

SEC source: 0000950170-24-068906 · ownership.xml · derivative · entry 5

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,000 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

SEC source: 0000950170-24-068906 · ownership.xml · derivative · entry 4

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,000 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

SEC source: 0000950170-24-068906 · ownership.xml · derivative · entry 3

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

SEC source: 0000950170-24-068906 · ownership.xml · derivative · entry 2

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 141,011 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

SEC source: 0000950170-24-068906 · ownership.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.

SEC source: 0000950170-24-028788 · ownership.xml · nonDerivative · entry 4

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.20 to $46.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0000950170-24-028788 · ownership.xml · nonDerivative · entry 3

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.3025 to $46.3675, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0000950170-24-028788 · ownership.xml · nonDerivative · entry 2

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

SEC source: 0000950170-24-028788 · ownership.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

SEC source: 0001209191-23-037092 · doc4.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2033-06-13

F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc.

SEC source: 0000950170-23-026184 · ownership.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,475

Underlying: Common Shares · 18,475 shares

Expires 2033-06-01

F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.

SEC source: 0001209191-22-045421 · doc4.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,400

SEC source: 0001209191-22-039827 · doc4.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Shares · 18,000 shares

Expires 2032-06-27

F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders.

SEC source: 0001209191-22-038770 · doc4.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2032-06-13

F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 14, 2023 or (ii) the 2023 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc.

SEC source: 0001209191-21-053000 · doc4.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

SEC source: 0000899243-21-033814 · doc4.xml · nonDerivative · entry 2

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,171

SEC source: 0000899243-21-033814 · doc4.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,171

SEC source: 0000899243-21-033258 · doc4.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

SEC source: 0001209191-21-038573 · doc4.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2031-06-03

F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 4, 2022 or (ii) the 2022 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc.

SEC source: 0001209191-21-038063 · doc4.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Shares · 10,000 shares

Expires 2031-06-02

F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

SEC source: 0000899243-20-017886 · doc4.xml · derivative · entry 2

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Shares · 30,000 shares

Expires 2030-06-18

F2 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments beginning on July 18, 2020.

SEC source: 0001209191-20-033605 · doc4.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Shares · 10,000 shares

Expires 2030-05-31

F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

SEC source: 0000899243-20-017886 · doc4.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,011

Underlying: Non-Voting Common Shares · 141,011 shares

Expires 2030-01-19

F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments beginning on February 19, 2020. Prior to closing of the Issuer's initial public offering, such Non-Voting Common Shares will convert into Voting Common Shares and subsequently into Common Shares on a one-for-one basis.

SEC source: 0001209191-19-050131 · doc4.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Shares · 15,000 shares

Expires 2029-09-15

F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

SEC source: 0001171843-18-004455 · formfour.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Shares · 15,000 shares

Expires 2028-06-03

F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

SEC source: 0001171843-17-005067 · formfour.xml · nonDerivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.75 to $2.8458, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

SEC source: 0001171843-17-003446 · formfour.xml · derivative · entry 1

GANNON STEVEN · CIK 0001643085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,500

Underlying: Common Shares · 3,500 shares

Expires 2027-05-31

F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date.